NCT01927913View on ClinicalTrials.gov

Treatment of Iron Overload Requiring Chelation Therapy

PHASE2WithdrawnINTERVENTIONAL

0

Timeline

Start Date

November 20, 2014

Primary Completion Date

October 30, 2015

Study Completion Date

October 30, 2015

Conditions

Transfusional Iron OverloadIron OverloadIron ChelationBeta-thalassemiaTransfusional HemosiderosisIron Metabolism DisordersMetabolic Diseases

Interventions

DRUG

SPD602

32, 50 or 75 mg/kg/day BID, capsule

DRUG

Deferasirox

Per approved country specific label

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Shire

INDUSTRY

NCT01927913 - Treatment of Iron Overload Requiring Chelation Therapy | Biotech Hunter | Biotech Hunter